Sofinnova Investments, a healthcare investment firm, led a $170m round in BioAge, a clinical-stage biotechnology company, with participation from Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Andreessen Horowitz and Amgen Ventures. “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases. This funding will support us through key clinical milestones and data readouts for our lead compound azelaprag in obesity, as well as advance our earlier-stage metabolic aging pipeline. The azelaprag program highlights our discovery platform’s ability to identify novel approaches to treating metabolic disease,” Kristen Fortney, BioAge CEO and Co-Founder.